Pain Management

In 2023, drug overdose deaths sustained declines, but there are still disparities that need to be addressed to continue to decrease these numbers.

Chronic pain is associated with a significant financial burden, with an estimated cost placed at $650 billion annually in the US.

In an update to the Journal of Pain Research’s formative meta-analysis on pain management in the US, researchers focused on the racial and ethnic disparities in access to pain treatment.

Expert on pain medicine, Mark Garofoli, PharmD, BCGP, CPE, CTTS, joined Drug Topics to discuss trends in the safety and efficacy of OTC pain medications and what products patients often seek at the pharmacy.

According to poison control data, many children aged 0 to 17 experience toxicity from over-the-counter analgesics like ibuprofen and acetaminophen.

As pharmacists move away from opioids in pain management, researchers present the use of supplemental OTC products to assist patients’ acute pain.

Cebranopadol met its primary endpoint of reduction in pain intensity as measured by the Pain Numeric Rating Scale (NRS) area under the curve from 2 through 48 hours.

In a third installment of our interview series with Chris Robinson, MD, PhD, we looked at the future of pain management and emerging technologies being used for treatment.

In a search for new treatment and prevention strategies for pain in patients with fibromyalgia, researchers explored bioavailable nutraceuticals and phytochemicals like polyphenols.

Chris Robinson, MD, PhD, joined Drug Topics to discuss the importance of education in newly explored technologies for the treatment of pain.

Researchers explored the efficacy of a multidisciplinary pain management team for addressing patients with cancer-related pain.

Researchers investigated the pharmacological management of chronic orofacial pain and provided guidance on its proper treatment.

Physician with expertise in pain research discussed emerging technologies in the future of pain medicine and how they must be adapted to improve patient outcomes.

Experts gathered to explore the pathophysiology and therapeutic management of burn injury-induced pain.

Patients with musculoskeletal pain were treated with cryotherapy spray to assess its use in providing immediate and sustained pain relief.

Patients prescribed high-dose opioids were given the option to switch to buprenorphine in hopes of improving pain and reducing opioid dosage.

Researchers investigate the effects of subanesthetic doses of esketamine for the treatment of pain and cognition in patients undergoing surgery.

For patients with atopic dermatitis reporting moderate-to-severe scratching, researchers explored the efficacy of an AI-enabled wearable sensor with closed-loop haptic feedback.

Cardiovascular health is known to be associated with the probability of having active or developing migraine in the future.

Researchers conducted a review of clinical studies to better understand non-oral drugs for the treatment of pain related to herpes zoster.

Researchers asked adults with chronic pain and physicians their opinions on cannabis regulations.

Reducing the number of opioid prescriptions for patients with lower back pain did not result in an increased use of other, risky pain medications.

Assessing the management of chronic low back pain, researchers compared outcomes of healthy lifestyle care with current guideline-recommended care.

Researchers addressed unmet needs in the treatment of chronic pain for patients living with axial spondyloarthritis.

In a network meta-analysis, researchers compared the safety and efficacy of available analgesic treatment for treating acute pain in children.

A recent study found that edible or smoked cannabis use predicted little variability in pain relief.

In a systematic review, researchers explored how biofeedback impacted rehabilitation in patients experiencing chronic pain disorders.

Tocilizumab-anoh is the biosimilar formulation for ACTEMRA, a medication used to treat rheumatoid arthritis, COVID-19, and other diseases.

Axsome Therapeutics expects the therapy to be commercially available in the United States in approximately 4 months.

The decision makes the selective NaV1.8 pain signal inhibitor the first new class of medicine to treat acute pain in over 20 years.